Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Blood blood.2025030816.

https://doi.org/10.1182/blood.2025030816

Published: 2025

Includes: Supplemental data

Journal Articles

Machine learning-based body composition analysis for risk stratification in newly diagnosed diffuse large B cell lymphoma

Fabian Ullrich, René Hosch, Emre Kocakavuk, Hans Christian Reinhardt, Ulrich Dührsen, Andreas Hüttmann, Felix Nensa, Bastian von Tresckow

Blood (2025) 146 (Supplement 1): 897.

https://doi.org/10.1182/blood-2025-897

Published: 2025

Journal Articles

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Blood (2025) 146 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2025-1676

Published: 2025

Journal Articles

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Meng Wang, Joji Shimono, Shashwat Sahay, Chidimma Agatha Akpa, Christina Schniederjohann, Julia Richter, Peter-Martin Bruch, Ulrich Dührsen, Michael Hummel, Andreas Rosenwald, Wolfram Klapper, Sascha Dietrich, Ulrich Keller, Björn Chapuy

Blood (2025) 146 (Supplement 1): 50.

https://doi.org/10.1182/blood-2025-50

Published: 2025

Journal Articles

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

Daria Frank, Pradeep Kumar Patnana, Jan Vorwerk, Lianghao Mao, Lavanya Mokada Gopal, Noelle Jung, Thorben Hennig, Leo Ruhnke, Joris Maximillian Frenz, Maithreyan Kuppusamy, Robert Autry, Lanying Wei, Kaiyan Sun, Helal Mohammed Mohammed Ahmed, Axel Künstner, Hauke Busch, Heiko Müller, Stephan Hutter, Gregor Hoermann, Longlong Liu, Xiaoqing Xie, Yahya Al-Matary, Subbaiah Chary Nimmagadda, Fiorella Charles Cano, Michael Heuser, Felicitas Thol, Gudrun Göhring, Doris Steinemann, Jürgen Thomale, Theo Leitner, Anja Fischer, Roland Rad, Christoph Röllig, Heidi Altmann, Desiree Kunadt, Wolfgang E. Berdel, Jana Hüve, Felix Neumann, Jürgen Klingauf, Virginie Calderon, Bertram Opalka, Ulrich Dührsen, Frank Rosenbauer, Martin Dugas, Julian Varghese, Hans Christian Reinhardt, Nikolas von Bubnoff, Tarik Möröy, Georg Lenz, Aarif M. N. Batcha, Marianna Giorgi, Murugan Selvam, Eunice Wang, Shannon K. McWeeney, Jeffrey W. Tyner, Friedrich Stölzel, Matthias Mann, Ashok Kumar Jayavelu, Cyrus Khandanpour

Blood (2023) 142 (25): 2175–2191.

https://doi.org/10.1182/blood.2022015752

Published: 2023

Includes: Supplemental data

Journal Articles

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Blood (2022) 140 (Supplement 1): 777–778.

https://doi.org/10.1182/blood-2022-163454

Published: 2022

Journal Articles

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Erik Van Dijk, Jurriaan Janssen, Matias Mendeville, G. Tjitske Los-De Vries, Margaretha GM Roemer, Phylicia Stathi, Julia Richter, Yong Soo Kim, Wolfram Klapper, Ulrich Dührsen, Andreas Hüttmann, P. J Lugtenburg, Josée M. Zijlstra, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau, Bauke Ylstra

Blood (2022) 140 (Supplement 1): 9261–9263.

https://doi.org/10.1182/blood-2022-160052

Published: 2022

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Jakoba J Eertink, Gerben J.C Zwezerijnen, Sanne E Wiegers, Martine E.D Chamuleau, Pieternella Lugtenburg, Daphne De Jong, Bauke Ylstra, Matias Mendeville, Ulrich Dührsen, Andreas Hüttmann, Christine Schmitz, Julia Richter, Wolfram Klapper, Otto S Hoekstra, Henrica C.W de Vet, Ronald Boellaard, Josée M Zijlstra

Blood (2021) 138 (Supplement 1): 451.

https://doi.org/10.1182/blood-2021-145855

Published: 2021

Journal Articles

Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial

Heiner Zimmermann, Christian Koenecke, Martin H. Dreyling, Christiane Pott, Ulrich Dührsen, Dennis Hahn, Norbert Meidenbauer, Ingeborg A Hauser, Mathias J. Rummel, Dominik Wolf, Michael Heuser, Christian Schmidt, Peter Schlattmann, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Ralf Ulrich Trappe

Blood (2021) 138 (Supplement 1): 3555.

https://doi.org/10.1182/blood-2021-146823

Published: 2021

Journal Articles

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136544

Published: 2020

Journal Articles

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Ashwini M Patil, MSc, Stefanie Kesper, Vishal Khairnar, PhD, Marco Luciani, Michael Möllmann, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, PD, MD

Blood (2019) 134 (Supplement_1): 2537.

https://doi.org/10.1182/blood-2019-125331

Published: 2019

Journal Articles

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Blood (2019) 134 (Supplement_1): 3308.

https://doi.org/10.1182/blood-2019-129684

Published: 2019

Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 491.

https://doi.org/10.1182/blood-2019-129283

Published: 2019

Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Blood (2019) 134 (Supplement_1): 487.

https://doi.org/10.1182/blood-2019-122298

Published: 2019

Journal Articles

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Blood (2019) 134 (Supplement_1): 644.

https://doi.org/10.1182/blood-2019-129926

Published: 2019

Journal Articles

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Max Topp, MD, Tom Van Meerten, MD PhD, Roch Houot, MD PhD, Monique C. Minnema, Noel Milpied, MD, Pieternella J. Lugtenburg, MD PhD, Catherine Thieblemont, MD PhD, Martin Wermke, MD, Kevin Song, MD, Irit Avivi, MD, John Kuruvilla, MD, Ulrich Dührsen, Prof, MD PhD, Rachel Chu, PhD, Lianqing Zheng, PhD, Vicki Plaks, PhD, Anne Kerber, MD, Marie Jose' Kersten, MD PhD

Blood (2019) 134 (Supplement_1): 243.

https://doi.org/10.1182/blood-2019-126081

Published: 2019

Journal Articles

Pharmacologic LSD1 Inhibition Preserves Human Granulocytic While Expanding Monocytic Progenitors

Karlotta E Kahmann, Stefanie Kesper, Marco Luciani, Michael Möllmann, Hugh Y. Rienhoff, Jr., MD, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, MD

Blood (2018) 132 (Supplement 1): 2645.

https://doi.org/10.1182/blood-2018-99-113887

Published: 2018

Journal Articles

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Anas Younes, MD, Laurie H Sehn, MDMPH, Peter Johnson, MD, Pier Luigi Zinzani, MD, Xiaonan Hong, MD, Jun Zhu, Olga Samoilova, MD, Cheolwon Suh, Itaru Matsumura, MD, Andres Lopez-Hernandez, MD, Ulrich Dührsen, Prof, MD PhD, Catherine Thieblemont, MD, Jodi Carey, BSN, RN, Grace Liu, PhD, S. Martin Shreeve, MD PhD, Steven Sun, PhD, Jessica Vermeulen, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD

Blood (2018) 132 (Supplement 1): 784.

https://doi.org/10.1182/blood-2018-99-112988

Published: 2018

Journal Articles

Long-Term Survival after Transplantation in Patients with Chronic Myeloid Leukemia from HLA-Compatible Unrelated Donors: May the Stem Cell Source Influence the Outcome?

Michael Koldehoff, Prof, MD PhD, Ahmet H. Elmaagacli, Prof, MD PhD, Hellmut Dietmar Ottinger, MD PhD, Ulrich Dührsen, Prof, MD PhD, Dietrich W. Beelen

Blood (2018) 132 (Supplement 1): 5775.

https://doi.org/10.1182/blood-2018-99-118615

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

Machine learning-based body composition analysis for risk stratification in newly diagnosed diffuse large B cell lymphoma

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Pharmacologic LSD1 Inhibition Preserves Human Granulocytic While Expanding Monocytic Progenitors

A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Long-Term Survival after Transplantation in Patients with Chronic Myeloid Leukemia from HLA-Compatible Unrelated Donors: May the Stem Cell Source Influence the Outcome?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only